Accelerate Diagnostics (NASDAQ:AXDX) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a sell rating to a hold rating in a research note released on Monday morning.

Accelerate Diagnostics Price Performance

Shares of AXDX stock opened at $1.64 on Monday. The stock’s fifty day moving average price is $1.79 and its 200 day moving average price is $1.51. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $5.23. The company has a market cap of $41.07 million, a price-to-earnings ratio of -0.57 and a beta of 0.59.

Hedge Funds Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics at the end of the most recent quarter. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.